Quantification of the Time and Effort Required For Autologous Peripheral Blood Stem Cell Collection: A European Perspective

Outcome measures include number of visits for administration of mobilizing agents; duration (days) of administration of mobilizing agents; agents used as mobilizing agents; adverse events detected during mobilization; number of apheresis sessions; hours of apheresis sessions; attainment of CD34+ target (yes, no); days until CD 34+ target level was met. In addition, time-motion assessments will be obtained retrospectively (Part I) and concurrently (Part II) and included the total time to prepare the patient, perform apheresis and manage adverse events. Costs will be evaluated and quantified in terms of micro-costing group interviews with local hospital administration. The primary study end point is difference in mean time to perform apheresis (including apheresis related adverse events, if any) and costs to the hospital in terms of micro-costing per patient, between patients in the Pre-P versus P eras. Results: At the time of abstract submission, data collection is ongoing and results will be presented during the meeting. The key findings of this study will demonstrate the favorable impact of novel interventions on the number of apheresis procedures required to reach a target peripheral blood stem cell, and failure rate of mobilization, thus translating into reduced total transplant costs without increasing the toxicity.